Synaptogenix (NASDAQ:TAOX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Synaptogenix (NASDAQ:TAOX) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Synaptogenix Price Performance

Shares of NASDAQ TAOX opened at $5.70 on Friday. The stock has a market cap of $42.58 million, a PE ratio of -0.28 and a beta of 1.68. Synaptogenix has a 52-week low of $1.84 and a 52-week high of $11.98. The business has a 50-day moving average price of $4.71 and a 200 day moving average price of $5.82.

Synaptogenix (NASDAQ:TAOX) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of ($2.46) million for the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.